Working… Menu

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (AcSé)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02304809
Recruitment Status : Recruiting
First Posted : December 2, 2014
Last Update Posted : February 17, 2016
National Cancer Institute, France
Fondation ARC
Hoffmann-La Roche
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 2016
Estimated Study Completion Date : February 2022